The actual controller and controlling shareholder of Susser Bio are involved in the lawsuit

December 7, Seselsu Bio issued an announcement regarding litigation involving actual controllers and controlling shareholders. According to the announcement, on October 29, 2020, SSE disclosed the "Announcement on the Freezing of Part of the Shares of The Controlling Shareholders" on the Shanghai Stock Exchange, and GSC New Ventures and Xinxin First Phase have applied to the Shanghai Second Intermediate People's Court for pre-suit property preservation of the company's actual controllers, Fang Yongsheng, Liang Xilin, and the company's controlling shareholder Leap Kang Bio, and the court has frozen the 4 million shares held by Leap Kang Bio.As of the date of the announcement, Gaoke Xinsheng and Xinxuan Phase I have filed a lawsuit with the Second Intermediate People's Court of Shanghai, and the case has not yet been heard. Liang Xilin and Fang Yongsheng held 45 million yuan and 5 million yuan of shares of Leap Kang Bio, respectively, have been frozen.In December 2016, the two plaintiffs, Gaoke Xinsheng and Xinxin First Phase, as investors, signed relevant agreements with the three defendants, Fang Yongsheng, Liang Xilin and Leap Kang Bio, and Gaoke Xinsheng and Xinxin First Phase jointly subscribed for a new contribution of RMB1260.0321 million from LeapCom Bio, with a subscription price of RMB100 million, of which gao The new subscription of Leap Kang Bio was RMB441.0112 million, the subscription price was RMB35 million, and the new subscription of Leap Kang Bio was RMB819.0209 million, and the subscription price was RMB65 million, all of which were paid in the month. At the same time, the two sides for including the right to return to sale after listing and other matters agreed.On July 13, 2020, Gicco New Ventures and Xinxin Phase I asked the defendant to purchase the full partnership share of its Leap Kang Bio. Among them, Gaoke Xinsheng holds 7.0449% of the partnership share of LeapCom Bio, corresponding to the issue of 109.9004 million shares of Sebo Bio, and Syntech Holds 13.0833% partnership share of Leap Kang Bio, corresponding to Theo Bio has issued 204.0995 million shares. The return price requested by GC Created is 269 million yuan, and the return price required by the first phase of the new phase is 499 million yuan.The plaintiff's claim is as follows: (1) ordered Fang Yongsheng, Liang Xilin and Leap Kang Bio to jointly pay the partnership share of Gaoke Xinsheng a return price of RMB 269 million, and to pay the partnership share of the first phase of the partnership share of RMB499 million, a total of 768 million yuan;(2) To order housing immorality, Liang Xilin, Leap Kang bio to gaoke New Ventures, Xinxin first-phase compensation due to late payment of the return of the sale price caused by the loss of interest;(3) Order Leap Kang Bio to assist Gaoke Xinxin and Xinxin First Phase respectively to handle the registration procedures for the pledge of 109.9004 million shares and 204.0995 million shares held by Leap Kang Bio respectively (the pledge rights holders are Gaoke Xinxin and Xinxin First Phase, and the pledge person is Leap Kang Bio);(4) The legal costs of the case shall be borne jointly by the three defendants.The company and the controlling shareholders, the actual controllers in business, personnel, assets, institutions, finance and other aspects of their respective independence, the lawsuit did not have a significant adverse impact on the company's production and operation. At present, the company is operating well, the company's net profit in the first three quarters of 2020 has significantly exceeded the level of the full year 2019, 2020 net profit will be greater than the previous year. At present, the above-mentioned cases have not yet been heard and have not yet produced the results of the proceedings. The controlling shareholders of the Company acknowledge that this lawsuit will not result in a change in the Company's control. (
Biological Bulletin)
)